跳至主要内容
临床试验/RBR-10myxdss
RBR-10myxdss尚未招募未知

se of the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) short version and MDASI in patients with Cancer patients submitted to oral antineoplastic medications such as Tyrosine Kinase Inhibitors: a comparative study of the 2 scales

niversidade Federal de São Paulo0 个研究点开始时间: 2022年11月7日最近更新:
适应症

试验速览

阶段
未知
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Intervention

入排标准

年龄范围
18Y 至 0(—)

入选标准

  • older than 18 years; being treated with TKI alone as anticancer therapy, orally and for 3 months or more; being diagnosed with one of three cancers: kidney, lung, or chronic myeloid leukemia; Performance status between 0 and 2, evaluated according to the Eastern Cooperative Oncologic Group – ECOG scale

排除标准

  • multiple comorbidities (3 or more), partial completion of one of the data collection instruments

研究者

发起方
niversidade Federal de São Paulo

相似试验